FDA Panel Weighs Safety Concerns With Using COVID-19 Vaccines In Kids

FDA’s vaccine advisers failed to reach an agreement Thursday (June 10) on whether COVID-19 vaccines should be authorized for emergency use in pediatric populations, namely those ages 6 months to 12 years, or whether pediatric indications should go through the full vaccine licensure process. They also debated whether trials in pediatric and adolescent populations should include larger safety databases to better capture rare adverse events, like the occurrences of myocarditis and pericarditis that have been reported in 12- to 24-year-olds...